Land: Ástralía
Tungumál: enska
Heimild: Department of Health (Therapeutic Goods Administration)
olanzapine, Quantity: 2.5 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: microcrystalline cellulose; lactose; hyprolose; magnesium stearate
Oral
28
(S4) Prescription Only Medicine
OLANZA tablets are indicated for ? Treatment of schizophrenia and related psychoses. ? Short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar I disorder. ? Preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.
Visual Identification: Light yellow to yellow coloured, slightly mottled, round, biconvex tablets, debossed with 'O4' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2020-07-01